Engineering Conferences International

ECI Digital Archives
Vaccine Technology IV

Proceedings

Spring 5-23-2012

Systematically Characterizing Adventitious Agent
Tests for Biologics
Rebecca Sheets
National Institute of Allergy & Infectious Diseases

Follow this and additional works at: http://dc.engconfintl.org/vaccine_iv
Part of the Biomedical Engineering and Bioengineering Commons
Recommended Citation
Rebecca Sheets, "Systematically Characterizing Adventitious Agent Tests for Biologics" in "Vaccine Technology IV", B. Buckland,
University College London, UK; J. Aunins, Janis Biologics, LLC; P. Alves , ITQB/IBET; K. Jansen, Wyeth Vaccine Research Eds, ECI
Symposium Series, (2013). http://dc.engconfintl.org/vaccine_iv/34

This Conference Proceeding is brought to you for free and open access by the Proceedings at ECI Digital Archives. It has been accepted for inclusion in
Vaccine Technology IV by an authorized administrator of ECI Digital Archives. For more information, please contact franco@bepress.com.

Conference Name

Systematically Characterizing
Adventitious Agent Tests for Biologics
May 23, 2012

Date

ECI Vaccine Technology IV
Albufiera, Portugal

CAPT Rebecca Sheets, Ph.D., USPHS
USNIH/NIAID

Outline
• Background and Context of Projects
• Bovine and Porcine Viruses
• Scope and Purpose of Work
• Methods
• Results and Conclusions
• “Routine” adventitious virus tests
• Scope and Purpose of Work
• Planning
• Implementation
• Results and Conclusions
• Future Considerations
• Summary
2

Background and Context
• DAIDS and IABS co-sponsored Vaccine Cell
Substrates 2004
• 3 day conference, 6 themes
• 2 of those themes were Bovine (& porcine) Viruses in
raw materials, Viral Adventitious Agent Test Methods
• One purpose of conference was to identify research
gaps that preclude decision-making, since DAIDS is
a funding organization that could potentially fund
gap-filling research
• Progress on Cell Substrate policy was required to
facilitate the development of HIV/AIDS vaccine
candidates (novel approaches, novel vectors, novel
cell substrates)
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Background and Context (2)
• Panel discussions led to recommendations
• Bovine (and porcine) viruses
• A systematic consideration should be given to
the agents listed in 9 CFR with regard to
relevance to use of animal-derived raw materials
in production of human biologicals
• Viral Adventitious Agent Test Methods
• Sensitivity and breadth of existing tests are
presumed from historical experience and should
be evaluated systematically
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Bovine and Porcine Viruses
Scope and Purpose of Work
• Review literature
• To determine whether the bovine viruses specified in
9 CFR 113.47 are capable of infecting humans or
display human host range (e.g., by infecting human
cells in culture or producing antibodies in natural- or
laboratory-exposed humans)
• To determine if there are other bovine viruses of
concern (displaying bovine and human host range)
that could be predicted to be detected by the 9 CFR
procedures (including CPE and HAd/HAg on
indicator cells used in test)
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Bovine and Porcine Viruses
Scope and Purpose of Work (2)
• Review literature
• To identify porcine viruses (in addition to porcine
parvovirus) having human host range and could
contaminate porcine trypsin
• To predict whether these porcine viruses would be
detected by the 9 CFR test methods

 Strictly a literature review and predictions would
need to be verified in the laboratory – outside
scope of project
 Included more than traditionally zoonotic viruses
because biologicals are administered by routes
that would bypass normal host defenses to natural
infections
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Bovine and Porcine Viruses
Methods
All Vertebrate viruses
Step 1

1. Naturally infects cattle or swine
2. Antibodies detected and/or
3. Infects bovine/porcine cells in culture

Viruses with Bovine or
Porcine host range

Step 2

Viruses with Bovine and
Human host range
(Viruses of Concern)
Bovine viremia or
fetal transmission

1. Naturally infects humans
2. Human anitbodies detected and/or
3. Infects human cells in culture

Viruses with Porcine
and Human host range
(Viruses of Concern)

Step 3a

Porcine viremia likely
not predictive of trypsin
contaminationa

Step 3b
Potential to contaminate
porcine trypsin
(Omitted)

Potential to
Contaminate FBS
Step 4

Predict detection of viruses
not specified by 9CFR

Yes
Viruses that could
be detected by
9CFR test
Yes

Viruses can infect cells used in
9CFR
Bovine - VERO and BT
Porcine - VERO, ST, PK cells

CPE or HA in VERO cells
OR
CPE in BT cells

No
Viruses that could
contaminate bovine serum
OR
porcine trypsin and may not
be detected by 9CFR
No
Viruses to consider for
additional evaluation
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Bovine and Porcine Viruses
Results and Conclusion
• Some bovine viruses in the 9 CFR test are
probably not important to human biologicals, but
many more bovine and porcine viruses than are
predicted to be detectable by the 9 CFR tests may
be of concern
• Even within virus families, one or more members
may be detected, but others may not
• Even within a virus type (e.g., reoviruses), it isn’t
clear that all strains would be detected (e.g., if
Reo-3 is detected by the specific antisera used for
IFA, what is sensitivity to detect Reo-1 and -2?)
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Predicted to
cause CPE or
HAd in 9CFR

Viruses with
HHR

Porcine
Predicted to
cause CPE or
HAd in 9CFR

May
contaminate
FBS

Capable of
fetal
transmission

Bovine
Viruses with
HHR

Virus family

IFA read out in
9CFR testing

Bovine and Porcine Viruses
Results and Conclusions (2)

Adenoviridae
Anelloviridae
[proposed family
name]
Bornaviridae

At least one
member of
the family has
the attribute

Bunyaviridae
Caliciviridae
Circoviridae
Coronaviridae
Filoviridae
Flaviviridae
Hepeviridae
[proposed family
name]
Herpesviridae

Unknown

Orthomyxoviridae
Papillomaviridae

Likely

Paramyxoviridae
Parvoviridae
Picornaviridae
Polyomaviridae
Poxviridae
Reoviridae
Retroviridae
Rhabdoviridae
Togaviridae

Unknown
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Bovine and Porcine Viruses
Results and Conclusion (3)
• Recommendations (alternatives)
• No change
• Modify 9 CFR tests
• Require testing of fetal bovine sera for anti-viral
antibodies
• Require gamma irradiation of bovine sera, use
recombinant trypsin, use serum-free or animalderived materials-free media
• Consider incorporating the minipool concept
• Consider additional tests for specific viruses
• Incorporate virus-family testing
• Consider using new test methods
• And more
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Bovine and Porcine Viruses
Find out more
This study is published in Biologicals 39(6)359-69
Nov. 2011
“Evaluation Of The Human Host Range Of Bovine
And Porcine Viruses That May Contaminate Bovine
Serum And Porcine Trypsin Used In The
Manufacture Of Biological Products”
Carol Marcus-Sekura, James Richardson, Nandini
Sane, Rebecca Harston, Rebecca Sheets
• CMS – BASI (sub-contract)
• JR, NS, RH – Advanced BioScience Laboratory
(prime contractor)
• Also acknowledge: Jack Hill, HMJF/DAIDS, Renita
Johnson-Leva, ABL
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“Routine” Adventitious Virus Tests
Scope of Work

• Systematically characterize the breadth &
sensitivity of the “routine” adventitious virus tests
• In vivo (so-called “Inapparent Viruses” Test)
• In vitro (cell culture)
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“Routine” Adventitious Virus Tests
Purpose of Work
• Provide regulators and manufacturers with
information needed for decision-making
• Such info normally comes from assay validation

• Provide baseline data to serve as basis of
comparison for new methods
• Provide protocols and viral stocks to permit
“direct” comparisons by developers of new
methods
• Determine “value added” by in vivo methods in
consideration of NIH’s 3 R’s policy
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“Routine” Adventitious Virus Tests
Planning Phase
• A panel of experts was convened
• Panel discussed
• Project utility
• Project questions
• Design and methods
• Practical considerations
– Though not intended to support a regulatory filing,
study should be conducted in accordance with Good
Laboratory/Manufacturing Practices (GLP/GMP)
– Take a matrix (checkerboard) approach
– Selected choice of viruses
– Viral stocks must be cultured and titered, recognizing
potential bias this introduced into study design
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“Routine” Adventitious Virus Tests
Methods
• In Vitro tests
• monolayers of at least 3 cell types, look for CPE
• tests for hemadsorption and hemagglutination
or immunofluorescence at end of culture period
• In Vivo tests
• adult and suckling mice
• when appropriate
– embryonated hens’ eggs
– guinea pigs
– rabbits
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“Routine” Adventitious Virus Tests
Breadth & Sensitivity
• These tests were developed for clinical
diagnostics in mid-20th century
• Initially used to detect SPECIFIC adventitious
agents
• Use expanded to broad general screening assays
• Breadth/sensitivity has not been systematically
assessed and published
• Not validated in the manner currently developed
assays would be required
• No regulatory requirements to do so and costly to
do
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“Routine” Adventitious Virus Tests
Matrix (Checkerboard) approach
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“Routine” Adventitious Virus Tests
Implementation Phase
• The prime contractor, Advanced BioScience
Laboratories, awarded task to Charles River Labs to
implement this project
• Compliant with Good Laboratory/Manufacturing
Practices
• Experienced with routine adventitious agent
testing
• In vivo and in vitro capabilities
• Virology expertise to prepare and characterize
viral stocks required
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“Routine” Adventitious Virus Tests
Implementation Phase (2)
• Viral stocks prepared in cell culture
• Titered
• Characterized for purity & identity
• In vivo testing
• Test at highest concentration for breadth
• If positive, sensitivity determined by titration
(dilutions)
• In vitro testing
• Breadth and sensitivity
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“Routine” Adventitious Virus Tests
In Vitro Adventitious Virus Assay

20

“Routine” Adventitious Virus Tests
In Vivo Adventitious Virus Assay
• Study design driven by ethical considerations
• Current acceptance criteria of 80% survival rate was
used
• LOD was defined as the virus titer resulting in < 20%
mortality (LD20)
• Initial study used undiluted stock virus
• Titration study determined LD20 for each virus sample
• multiple inoculation groups of 10 mice and 10 eggs each received
virus at various titers (determined by in vitro titration) to see which
resulted only in < 20% mortality

• To minimize cross-contamination
• One virus per room at any given time
• Performed in a Class II Biological Safety Cabinet
• Animals were housed in isolators in filter-topped Microisolator®
cages in a negative pressure work area (100% exhausted)
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“Routine” Adventitious Virus Tests
Results and Conclusions
The results can answer
questions such as:
• Is using two human
cell lines useful?
• Is a 14-day in vitro
test sufficient or are
28 days needed?

• Yes, MRC-5 & HeLa had
different sensitivities,
sometimes one was better,
sometimes the other

• 28 days more sensitive
in some cases

• Is sub-passage useful • No, for the viruses
for suckling mouse
tested
test sensitivity?
• Which is more
sensitive – in vitro or
in vivo?

• With the exception of flu, the
in vitro tests were always
more sensitive, generally by
logs, sometimes the
difference between
detecting and not detecting
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“Routine” Adventitious Virus Tests
Results and Conclusion
Vero
CPE
Ad41
Ad5
BVDV*
BPIV-3
Coxsackie A
Coxsackie B
Echovirus
Influenza A
HSV-1
Measles
Mumps
Rhinovirus
Rubella
Simian CMV
SV-40
VSV

HA

MRC-5
CPE

HA

HeLa
CPE

HA

* BVDV not tested
for HA, but by IFA,
only + on BT
(control cells) and
not indicator cells
lowest
concentration
reliably detected
1 log higher than
lowest
concentration
2 logs higher
than lowest
concentration
3 logs higher
than lowest
concentration
only undiluted
stock reliably
detected (LOD
pending)
not
detected

23

“Routine” Adventitious Virus Tests
In Vivo Adventitious Virus Assay (2)
Virus↓
Test→

Vero
CPE

MRC-5
HA

CPE

HeLa
HA

CPE

HA

Suckling Mice

Eggs

Original

Allantoic

Subpassage

Yolk Sac

Death

HA

Death

Coxsackie A 10
6.3x106

ND

10

100

10^5

ND

ND

ND

nt

nt

nt

Measles
9.3x105

0.01

0.01

10

1

0.1

0.1

nt

nt

ND

ND

ND

Echovirus
2x107

0.01

0.01

0.01

0.01

100

UD

ND

ND

nt

nt

nt

Influenza A
6.3x107

UD

UD

UD

1

ND

ND

nt

nt

0.1

0.01

0.001

LOD or LD20 values given
ND – not detected, negative at highest concentration
UD – Undiluted
nt – not tested
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“Routine” Adventitious Virus Tests
Outcomes/Deliverables
• Viral stocks will be made available through the
NIAID/DAIDS Reagent Resource Support Program
for AIDS Vaccine Development
• http://www.niaid.nih.gov/topics/hivaids/research/v
accines/resources/reagent/pages/default.aspx
• A research repository, not a regulatory authority
control lab reagent repository
• Not international reference materials, but research
reagents
• Protocols for virus preparation, titration, and for in
vivo and in vitro test methods will also be made
available
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“Routine” Adventitious Virus Tests
Future Considerations
• Provide developers of new methods with viral
stocks/protocols/baseline data
• Complete the missing cells of the matrix
• Expand the list of viruses to new viral families
• Replicate with multiple strains of a particular virus
• Test field isolates
• Most relevant to bovine/porcine viruses and to
products made in primary cell cultures/tissues/
animals
• Culture-adapted strains relevant to cell culture-derived
products, because contaminant would best amplify
and contaminate product, if adapted to the production
cell culture
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Summary
• Two of several NIAID-funded projects on adventitious
agent testing highlighted in this talk
• Bovine and Porcine Viruses
– Publication in Biologicals 39(6)359-69 Nov. 2011

• “Routine” Adventitious Virus Tests
– Will be published
– Viral stocks will be available as research reagents
– Protocols will also be available

• Additional activities not highlighted
• CBER/OVRR 2010 Guidance on cell substrates
• WHO 2010 Guidance on cell substrates
• Inter-Agency Agreement with CBER
• Welcome opportunities to collaborate or continue
progressing cell substrate, adventitious agent testing,
and 3 R’s policy issues
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“Routine” Adventitious Virus Tests
Adult Mice Test Methods
• Originally performed for purpose of detecting
LCMV or other viruses
• >20 adult mice
• i.p. with 0.5 mL, i.c., with 0.03 mL
• Mice must survive 21 days
• >80% survival
• No sign of viral infection
• Believed to be capable of detecting LCMV,
coxsackieviruses, flaviviruses, rabies

30

“Routine” Adventitious Virus Tests
Suckling Mice Test Methods
• Originally performed for purpose of detecting
Coxsackieviruses (particularly type A)
• >20 mice less than 24 hours old
• i.c., 0.01 mL, i.p., 0.1 mL
• 14 days
• Subinoculation into additional mice for 14 days
• Mice must survive
• >80% survival both inoculations
• No signs of viral infection

• Believed to be capable of detecting
coxsackieviruses, other picornaviruses (polioviruses,
echoviruses), alphaviruses, herpesviruses (HSV),
flaviviruses, rabies, many murine agents, others
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“Routine” Adventitious Virus Tests
Embryonated Hens’ Eggs Test Methods
• 10-11 day-old embryos, 0.5 mL allantoic route, 3
days, HA
• Believed to be capable of detecting orthomyxoviruses
(influenzaviruses), paramyxoviruses (mumps,
measles, parainfluenzaviruses), alphaviruses

• 6-7 day-old embryos, 0.5 mL yolk sac route, >9
days, survival
• Believed to be capable of detecting herpesviruses
(HSV), poxviruses, rhabdoviruses, rickettsiae,
mycoplasmas, bacteria
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“Routine” Adventitious Virus Tests
Preparation of Virus Stocks
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“Routine” Adventitious Virus Tests
In Vivo Adventitious Virus Assay (2)
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